National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost Effectiveness of Rivaroxaban (Xarelto®) for the prevention of stroke in atrial fibrillation.

Rapid Review

Commenced Completed Outcome
17/08/2011 31/08/2011 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
11/11/2011 02/4/2012  Reimbursement not Recommended

2/4/2012

The NCPE do not believe that rivaroxaban is cost effective for this indication at the submitted price.

Rivaroxaban for AF summary

19/6/2012

Following the NCPE pharmacoeconomic assessment (2/4/2012) the manufacturer reduced the price of rivaroxaban (23/5/2012).  At this revised price we now consider rivaroxaban cost effective for this indication.  A positive recommendation was made on the 19/6/2012.